Lilly Drug Beats Ozempic in Trial
Eli Lilly reported that its experimental obesity drug retatrutide outperformed Novo Nordisk's Ozempic in blood sugar control and weight loss during a late-stage trial. Patients taking retatrutide achieved double the weight loss of those on Ozempic.
Xurve View
Insights:
Xurve View
ELI LILLY & CO said its experimental obesity drug retatrutide outperformed NOVO NORDISK A/S-B's Ozempic, delivering double the weight loss in a late-stage diabetes study.
